Literature DB >> 22711906

Vaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.

Anne F Rositch1, Michael G Hudgens, Danielle M Backes, Stephen Moses, Kawango Agot, Edith Nyagaya, Peter J F Snijders, Chris J L M Meijer, Robert C Bailey, Jennifer S Smith.   

Abstract

BACKGROUND: Little is known about type-specific associations between prevalent human papillomavirus (HPV) infections and risk of acquiring other HPV types in men. Data on natural clustering of HPV types are needed as a prevaccine distribution to which postvaccine data can be compared.
METHODS: Using data from a randomized controlled trial of male circumcision in Kisumu, Kenya, adjusted mean survival ratios were estimated for acquisition of any-HPV, high-risk (HR) HPV, and individual HR-HPV types among men uninfected as compared to those infected with vaccine-relevant HPV types 16, 18, 31, 45, 6, or 11 at baseline.
RESULTS: Among 1097 human immunodeficiency virus-negative, uncircumcised men, 2303 incident HPV infections were detected over 2534 person-years of follow-up. Although acquisition of individual HR-HPV types varied by baseline HPV type, there was no clear evidence of shorter times to acquisition among men without vaccine-relevant HPV-16, -18, -31, -45, -6, or -11 infections at baseline, as compared to men who did have these infections at baseline.
CONCLUSIONS: These prospective data on combinations of HPV infections over time do not suggest the potential for postvaccination HPV type replacement. Future surveillance studies are needed to definitely determine whether elimination of HPV types by vaccination will alter the HPV type distribution in the population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711906      PMCID: PMC3491740          DOI: 10.1093/infdis/jis406

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

1.  Concurrent and sequential acquisition of different genital human papillomavirus types.

Authors:  K K Thomas; J P Hughes; J M Kuypers; N B Kiviat; S K Lee; D E Adam; L A Koutsky
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

2.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

3.  GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes.

Authors:  Adriaan J C van den Brule; René Pol; Nathalie Fransen-Daalmeijer; Leo M Schouls; Chris J L M Meijer; Peter J F Snijders
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 4.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

5.  Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection.

Authors:  M C Rousseau; J S Pereira; J C Prado; L L Villa; T E Rohan; E L Franco
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

6.  PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems.

Authors:  W Qu; G Jiang; Y Cruz; C J Chang; G Y Ho; R S Klein; R D Burk
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

7.  A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types.

Authors:  K L Liaw; A Hildesheim; R D Burk; P Gravitt; S Wacholder; M M Manos; D R Scott; M E Sherman; R J Kurman; A G Glass; S M Anderson; M Schiffman
Journal:  J Infect Dis       Date:  2000-11-16       Impact factor: 5.226

8.  Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea.

Authors:  Hai-Rim Shin; Silvia Franceschi; Salvatore Vaccarella; Ju-Won Roh; Young-Hee Ju; Jin-Kyoung Oh; Hyun-Joo Kong; Seo-Hee Rha; Se-Il Jung; Jung-Il Kim; Kap-Yeol Jung; Leen-Jan van Doorn; Wim Quint
Journal:  J Infect Dis       Date:  2004-07-01       Impact factor: 5.226

9.  Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

Authors:  Gloria Y F Ho; Yevgeniy Studentsov; Charles B Hall; Robert Bierman; Leah Beardsley; Michele Lempa; Robert D Burk
Journal:  J Infect Dis       Date:  2002-08-28       Impact factor: 5.226

10.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more
  8 in total

1.  Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.

Authors:  Talía Malagón; Philippe Lemieux-Mellouki; Jean-François Laprise; Marc Brisson
Journal:  Am J Epidemiol       Date:  2016-12-07       Impact factor: 4.897

2.  Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity.

Authors:  Sylvia L Ranjeva; Edward B Baskerville; Vanja Dukic; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano; Greg Dwyer; Sarah Cobey
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-05       Impact factor: 11.205

3.  Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.

Authors:  Mahboobeh Safaeian; Ana Cecilia Rodriguez
Journal:  Am J Epidemiol       Date:  2014-10-29       Impact factor: 4.897

4.  Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Luisa L Villa; Harriet Richardson; Ann N Burchell; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2016-06-02       Impact factor: 5.226

5.  Risk of HIV acquisition among circumcised and uncircumcised young men with penile human papillomavirus infection.

Authors:  Anne F Rositch; Lu Mao; Michael G Hudgens; Stephen Moses; Kawango Agot; Danielle M Backes; Edith Nyagaya; Peter J F Snijders; Chris J L M Meijer; Robert C Bailey; Jennifer S Smith
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

Review 6.  HPV vaccines: a controversial issue?

Authors:  A F Nicol; C V Andrade; F B Russomano; L L S Rodrigues; N S Oliveira; D W Provance
Journal:  Braz J Med Biol Res       Date:  2016-04-08       Impact factor: 2.590

7.  Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women.

Authors:  Joaquin Luna; Manuel Plata; Mauricio Gonzalez; Alfonso Correa; Ivete Maldonado; Claudia Nossa; David Radley; Scott Vuocolo; Richard M Haupt; Alfred Saah
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  Prevalence and Risk Factors of Human Papillomavirus in Male Patients: A Systematic Review and Meta-Analysis.

Authors:  María Inmaculada Rodríguez-Álvarez; Jose L Gómez-Urquiza; Husein Husein-El Ahmed; Luis Albendín-García; Juan Gómez-Salgado; Guillermo A Cañadas-De la Fuente
Journal:  Int J Environ Res Public Health       Date:  2018-10-10       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.